logo
RFK Jr.'s firing of U.S. immunization committee worrisome, Canadian scientists say

RFK Jr.'s firing of U.S. immunization committee worrisome, Canadian scientists say

CTV News11-06-2025
Health and Human Services Secretary Robert F. Kennedy Jr. and his wife Cheryl Hines talk to guests before President Donald Trump speaks during a summer soiree on the South Lawn of the White House, Wednesday, June 4, 2025, in Washington. (AP Photo/Alex Brandon)
TORONTO — Canadian doctors and scientists say Robert F. Kennedy Jr.'s firing of an immunization advisory committee south of the border is worrisome.
On Monday, the U.S. health and human services secretary — a longtime anti-vaccine advocate — said he will appoint new members to the scientific group that advises the Centers for Disease Control and Prevention about vaccination.
Angela Rasmussen, a virologist at the University of Saskatchewan, said Tuesday that the move will foster more false anti-vaccine beliefs, not only in the U.S. but also in Canada.
'It creates a culture in which anti-vaxx beliefs are more accepted and challenged a lot less. And also it creates an environment where there's an alternative to an evidence-based recommendation framework,' she said.
Even though Kennedy's new appointments will make vaccine recommendations specific to the United States, any disinformation could also feed vaccine hesitancy among Canadians, Rasmussen said.
'We have a lot of the same anti-vaxx sentiment up here. Certainly this will at the very least empower (that),' she said.
Rasmussen said current measles outbreaks in both countries show the consequences of disinformation that leads to parents not immunizing their children against preventable diseases.
She said Canada could also experience some fallout if the new committee pulls back vaccination recommendations, because manufacturers may cut back on production and that could lead to shortages.
'There's a lot of potential for really, really damaging vaccine access throughout the U.S. and potentially around the world because the U.S. market has a big impact on what vaccine manufacturers are actually going to make and manufacture,' she said.
'There's so many ways that this can end up really badly for vaccination in general. And it really causes me a lot of concern.'
Rasmussen said the firing of the advisory committee members is just the latest in a series of anti-public health actions Kennedy has taken.
'It's a death by a thousand cuts,' said Rasmussen, who is American and moved to Canada during the pandemic to work at the University of Saskatchewan's Vaccine and Infectious Disease Organization.
U.S. President Donald Trump's administration has already cut billions of dollars in research grants at the National Institutes of Health.
In May, the administration cancelled a contract with mRNA vaccine manufacturer Moderna to develop a vaccine against potential pandemic influenza viruses, including H5N1 avian flu.
'It just seems that there is a top-down approach that views mRNA vaccines in particular — vaccination in general, but mRNA vaccines in particular — with distrust and is trying to dismantle that particular avenue of medical research,' said Dr. Jesse Papenburg, a pediatric infectious diseases specialist at Montreal Children's Hospital.
Papenburg, who is a member of Canada's National Advisory Committee on Immunization but was not speaking on its behalf, said although the Moderna contract cancellation and the firing of the U.S. vaccine advisory committee members are two separate actions, they're both concerning as Canada tries to prepare for potential human-to-human transmission of H5N1.
'Both are potentially very dangerous when it comes to America's and the world's ability to respond to emerging infectious diseases for which vaccines could be a useful medical countermeasure,' he said.
— With files from The Associated Press
This report by The Canadian Press was first published June 11, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OC Transpo scrapping youth passes on Sept. 1, charging 11-19 year-olds the same fare as adults
OC Transpo scrapping youth passes on Sept. 1, charging 11-19 year-olds the same fare as adults

CTV News

time19 minutes ago

  • CTV News

OC Transpo scrapping youth passes on Sept. 1, charging 11-19 year-olds the same fare as adults

It will soon be the end of the road for OC Transpo's youth pass, as the City of Ottawa gets set to scrap the discounted pass for 11- to 19-year-olds at the end of August. In a memo to council, acting OC Transpo general manager Troy Charter reminded councillors the youth monthly pass will be discontinued as of September 1. 'Customers who currently have a Youth concession set on their Presto card will be charged an adult monthly pass on September 1,' Charter said. The youth monthly pass costs $104 a month, while an adult monthly pass costs $135 a month. Council approved the elimination of the youth monthly pass as part of the 2025 City of Ottawa budget in a bid to reduce a proposed budget deficit. The budget also eliminated free transit for 11 and 12-year-olds. A report for the Ottawa Student Transportation Authority shows the 2025-26 draft budget projected a $4.8 million increase in public transit costs due to the elimination of free transit for students 12 and under and scrapping the youth fare pass in September.

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store